Immunotherapy Combo Effective in Castration-resistant Prostate Cancer Mouse Models, Study Finds

Immunotherapy Combo Effective in Castration-resistant Prostate Cancer Mouse Models, Study Finds
Combining immune checkpoint inhibitors with drugs that target a population of myeloid-derived suppressor cells (MDSCs) may offer hope for men with metastatic prostate cancer who no longer respond to androgen deprivation therapy (ADT). Researchers at Houston's University of Texas MD Anderson Cancer Center conducted the mice study, which appeared in the journal Nature. "A significant number of advanced prostate cancer patients treated with a chemical castration therapy called androgen deprivation therapy experience relapse with relentless progression to lethal metastatic, castration-resistant prostate cancer," cancer biology professor Ronald DePinho, MD, said in a news release. "While immune checkpoint blockade therapy is effective in many cancers, it has been less successful for this particular form of prostate cancer, which has motivated a search for targeted therapies that overcome this resistance." In an attempt to find novel treatment options for men with metastatic castration-resistant prostate cancer, researchers first tested a combination of anti-CTLA-4 and anti-PD-1 immune checkpoint blockers in prostate cancer mouse models. But according to study first author Xin Lu, PhD, the combination showed only modest efficacy. The researchers knew that tumors often contain immunosuppressive cells that are associated with poor prognosis and response to immunotherapies. They hypothesized that blocking the immunosuppressive cells known as MDSCs could help these men. Whi
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *